$695mn refund for Takeda in Prevacid transfer pricing case
This article was originally published in Scrip
Executive Summary
Takeda's persistence in seeking a re-examination of a transfer pricing dispute with tax authorities in Japan has paid off handsomely, with the company set to receive a refund of ¥57.1 billion ($694.6 million) in the case, including tax and interest.